Key Stats for Elevance Stock
- Past-Week Performance: -0.05%
- 52-Week Range: $273.7 to $458.8
- Current Price: $291.5
What Happened?
Regulatory pressure on Elevance Health (ELV), the nation’s second-largest health insurer by membership, reached an inflection point when CMS extended a potential Medicare Advantage enrollment suspension deadline to May 30, while the company simultaneously reaffirmed adjusted EPS guidance of at least $25.50 for 2026, anchoring the stock at $291.48 against a 52-week high of $458.75.
On February 27, CMS notified Elevance of intent to impose intermediate sanctions, citing non-compliant risk-adjustment data submissions, a process by which insurers report member health status to receive appropriate government payments, for dates of service prior to April 3, 2023, sending shares down more than 3% to approximately $310 in premarket trading on March 2.
Elevance’s 2026 adjusted EPS guidance of at least $25.50 already embeds the financial impact of potential sanctions, and the company’s operating cash flow target of at least $5.5 billion provides capacity to fund $2.3 billion in share repurchases while sustaining its Carelon services platform, which generated nearly 60% revenue growth in 2025.
CFO Mark Kaye stated at the Barclays Global Healthcare Conference on March 10 that “we do not expect the financial impact of a resolution to change our capital deployment priorities or actions in 2026,” directly following the company’s March 10 SEC filing reaffirming the $25.50 adjusted EPS target.
Elevance’s path to at least 12% adjusted EPS growth in 2027 rests on Medicare Advantage margin recovery to at least 2% in 2026, Medicaid returning from a trough operating margin of -1.75%, and Carelon’s external pipeline scaling across oncology, severe mental illness, and specialty pharmacy programs funded by the company’s $2.3 billion repurchase commitment.
Wall Street’s Take on ELV Stock
The CMS sanctions deadline extension to May 30 buys Elevance time to resolve a dispute management frames as a historical policy disagreement, not a structural flaw, while normalized EPS is forecast to trough at $26.01 in 2026 before recovering 13.2% to $29.44 in 2027.
That EPS recovery, compounding further to $34.07 in 2028 and $45.23 by 2030, makes the forward earnings trajectory more durable than the stock’s 36% discount to its 52-week high suggests, with the current price implying just 11.2x 2026 trough earnings.
Eleven buys, three outperforms, and eight holds from 20 covering analysts converge on a mean price target of $380.95, implying 30.7% upside from $291.48, with zero sell ratings despite the regulatory overhang and two consecutive years of elevated medical cost trends.
The analyst spread runs from $332 on the low end, anchored to the risk that CMS sanctions extend beyond May 30 and suppress 2026 Medicare Advantage enrollment, to $474 on the high end, contingent on Medicaid rates closing the gap with mid-single-digit cost trend and Carelon’s external pipeline accelerating.
What Does the Valuation Model Say?
The TIKR mid-case target of $459.24 implies 57.6% total return over 4.8 years at a 10% annualized IRR, built on a conservative 2.7% revenue CAGR and net income margin recovery from 2.9% in 2026 to 3% by 2030, justified by management’s explicit 2027 commitment to at least 12% adjusted EPS growth off the 2026 trough baseline.
The market is pricing ELV as a structurally impaired insurer, but normalized EPS troughs at $26.01 in 2026 before recovering to $29.44 in 2027, a 13.2% rebound the current price does not reflect.
Carelon’s best-ever external growth year in 2025, with services revenue up nearly 60%, confirms the diversified earnings platform management cited as the foundation for that 2027 recovery, supporting the TIKR $459.24 target.
Mark Kaye’s March 10 reaffirmation that Q1 2026 earnings are tracking modestly above prior guidance, with Medicare, Medicaid, and ACA all running slightly favorable, signals the trough is functioning as management designed it, not deteriorating further.
A prolonged CMS sanction period past May 30 breaks the Medicare Advantage margin recovery assumption of at least 2% in 2026, which anchors the entire 2027 EPS rebound thesis.
The Q1 2026 earnings report in April is the first hard confirmation that Medicare and Medicaid cost trends are holding at mid-single-digit levels, the number to watch against the 90.2% medical loss ratio guidance midpoint.
Should You Invest in Elevance Health, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ELV stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Elevance Health, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ELV stock on TIKR for Free →
